However, because the reduction in HCC recurrence following the use of mTOR inhibitors has only been demonstrated in relatively small studies, high-quality studies, including well-designed multicenter studies, are needed to confirm the cancer preventive effects of mTOR inhibitors. This evidence concerns the gene MTOR and hepatocellular carcinoma.